Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharma reports 46% ORR in updated rezatapopt ovarian cancer interim data

Positive Impact 3 of 5 product/contract Written later

PMV Pharmaceuticals reported updated interim ovarian cancer data for rezatapopt from the Phase 2 pivotal portion of its PYNNACLE trial, with a 46% overall response rate among 76 evaluable patients. The company said recent FDA feedback supports submitting a new drug application for accelerated approval in platinum-resistant or refractory ovarian cancer in the first quarter of 2027, which sets a timeline for shareholders to track.

Key points

  • Overall response rate of 46% (35 of 76 patients) as of a May 14, 2026 data cutoff; median duration of response was 10.0 months
  • Company anticipates submitting an NDA for accelerated approval in the first quarter of 2027
  • Discontinuation due to treatment-related adverse events was 5%; full update on all Phase 2 cohorts planned for the fourth quarter of 2026 at a medical conference

The filing

CompanyPMV Pharmaceuticals, Inc. (PMVP)
Form8-K, current report
Filed with the SECAug 31, 2026, 4:06 PM ET
Accession number0001193125-26-376723

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 31, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.